The Valley Desk

Clinical trial reportCancer chemotherapy and pharmacologyPublished

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Thomas Jefferson University Hospital, with Jefferson Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Cancer chemotherapy and pharmacology
Published
Subject terms
Humans; Colorectal Neoplasms; Neoplasm Metastasis; Quinolines; GTP Phosphohydrolases; Proto-Oncogene Proteins B-raf; Membrane Proteins; Antineoplastic Combined Chemotherapy Protocols; Mutation; Adult; Aged; Aged, 80 and over
PubMed ID
40782152
Added to directory
Source checked

Report a correction or request removal